NCT01910519 - Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

November 30, 2015

Conditions

Influenza A Virus, H5N1 Subtype

Interventions

BIOLOGICAL

H5N1 vaccine plus AS03 adjuvant

"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."

BIOLOGICAL

H5N1 vaccine without adjuvant

"Administered vaccine: \[GlaxoSmithKline\] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."

Trial Locations (1)

30030

The Hope Clinic - Emory Vaccine Center, Decatur

All Listed Sponsors

collaborator

Emory University

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH